Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Melanoma 57Carcinoma, Renal Cell 19Leukemia, Myeloid, Acute 15Lymphoma, Non-Hodgkin 10Leukemia 10Kidney Neoplasms 10Skin Neoplasms 9Neuroblastoma 9Neoplasms 9Neoplasm Metastasis 9Lymphoma 9Breast Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 6Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Myelodysplastic Syndromes 5Congenital Abnormalities 5Uveal Melanoma 4Multiple Myeloma 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hodgkin Disease 4Hematologic Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2

Interventions

Cisplatin 30Pemetrexed 21Gemcitabine 11Radiotherapy 6Nivolumab 6Drug Therapy 6Cyclophosphamide 6Carboplatin 6durvalumab 4Vinorelbine 4Chemotherapy, Adjuvant 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3sodium thiosulfate 3sargramostim 3Ipilimumab 3Doxorubicin 3raltitrexed 2pembrolizumab 2cediranib 2SS1(dsFv)PE38 2Radiotherapy, Intensity-Modulated 2Psychiatric Rehabilitation 2Photochemotherapy 2Neoadjuvant Therapy 2Methotrexate 2Interferon-alpha 2Imatinib Mesylate 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gefitinib 2Everolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mesothelioma, Malignant × Interleukin-2 × Clear all
NCT02414945 2023-01-10

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

University Health Network, Toronto

Phase 1/2 Completed
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡